Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Down 5.42%
As of Friday, August 21, Scribe Therapeutics Inc.’s SCTX share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Commentary & Analysis
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 5.99%
As of Wednesday, August 19, Scribe Therapeutics Inc.’s SCTX share price has surged by 5.99%, which has investors questioning if this is right time to sell.Michael Rose
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 16.10%
As of Wednesday, August 19, Scribe Therapeutics Inc.’s SCTX share price has surged by 16.10%, which has investors questioning if this is right time to sell.Tudor Pop
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 9.72%
As of Tuesday, August 18, Scribe Therapeutics Inc.’s SCTX share price has surged by 9.72%, which has investors questioning if this is right time to sell.Michael Rose
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 26.17%
As of Tuesday, August 18, Scribe Therapeutics Inc.’s SCTX share price has surged by 26.17%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $643.8 | $292.6 | 39% |
|
| Shares Out (Mil) | 2.5 | 54.4 | 8% |
|
| Institutional Ownership | 18.2% | 93.2% | 9% |
|
| Float (Mil) | 6.8 | 40.2 | 15% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 215 | 544 | 45% |
|
| Price Change (52-week) |
na | 59.7% | na |
|
| Growth | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($36) | ($43) | 19% |
|
| EPS (TTM) | ($14.644) | ($1.400) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $498 | $164 | 34% |
|
| Valuation | SCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (54.6%) | 64.2% | 2% |
|
| Net Margin | (98.5%) | (75.9%) | 8% |
|
| ROA | (109.6%) | (47.5%) | 5% |
|
| ROE | 45.0% | (55.0%) | 92% |
|
| Liabilities to Assets | 158.9% | 29.6% | 98% |
|
| F-Score | 0 | 3 | na |
|
Scribe Therapeutics Inc. did not pass any screens on 8/21/2026.
